Office: South San Francisco, CA

Executive Assistant:
Christine Esguerra
(650) 238-5055

Kurt C. Wheeler
Managing Director

Kurt Wheeler has been Managing Director of Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, Mr. Wheeler was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 30 years of direct investment and industry experience within the healthcare sector.

Mr. Wheeler was founder and CEO of InControl (NASDAQ:INCL), a medical device company sold to Guidant. Prior to founding InControl he was a Principal with the Mayfield Fund focused on healthcare investing. Mr. Wheeler began his career with Elli Lilly & Co.

Mr. Wheeler holds a BA from Brigham Young University, and a MBA from Northwestern University’s Kellogg School.


Current Board Seats

Previous Board Seats

Cardiac Dimensions

CHF Solutions (acquired by Gambro)

Hemosense (AMEX:HEM) (acquired by Inverness Medical)

InControl (NASDAQ:INCL)(aquired by Guidant)

Intrathrerapeutics (acquired by Sulzer Medica)

Eyetech Pharmaceuticals (NASDAQ:EYET)

SenoRx (NASDAQ:SENO) (acquired by CR Bard)

Neuromed Pharmaceuticals (NASDAQ:ZLCS)

Somaxon Pharmaceuticals (NASDAQ:SOMX)

Zogenix (NASDAQ:ZGNX)

Clarus Board Seats

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Defined Exit
Team: Robert W. Liptak
Kurt C. Wheeler
Dennis Henner
Emmett Cunningham

Avillion

Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products. We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market.

Avillion Website

Fund: Clarus Lifesciences II, L.P.
Sector: Medical Device
Status: False
Type: Private
Team: Robert W. Liptak
Kurt C. Wheeler
Emmett Cunningham

Flowonix Medical

Flowonix Medical is focused on developing better treatment options for the 75 million Americans in chronic pain, more than diabetes, heart disease, and cancer combined.  Our first product for delivery of intrathecal medication, the Prometra® programmable implantable pump, is undergoing clinical trials.  Flowonix is headquartered in Mount Olive, NJ.

Flowonix Website

Fund: Clarus Lifesciences I, L.P.
Sector: Medical Device
Status: False
Type: Public
Team: Robert W. Liptak
Kurt C. Wheeler

Globus Medical, Inc. (NYSE:GMED)

Globus Medical, Inc. is focused on the development of products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Today Globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology.

Globus Website

Fund: Clarus Lifesciences II, L.P.
Sector: Medical Device
Status: True
Type: Private
Team: Kurt C. Wheeler
Emmett Cunningham

Neomend, Inc. acquired by Bard, Inc. in October 2012

Neomend, Inc. based in Irvine, CA has developed advanced surgical sealant, adhesion barrier, and applicator technologies based on its proprietary protein and polymer based hydrogel platform. Targeted surgical procedures include thoracic, spine, gynecology and general surgery. The company's initial product, ProGELTM Pleural Air Leak Sealant, has received FDA PMA approval and is the only indicated surgical sealant in the U.S. for sealing lung air leaks in thoracic surgery. ProGEL showed statistically significant reductions in intra-operative air leaks and length of hospital stay days in the PMA trial.

Fund: Clarus Lifesciences I, L.P.
Sector: Diagnostics & Tools
Status: False
Type: Public
Team: Scott Requadt
Michael Steinmetz
Kurt C. Wheeler

Oxford Immunotec, Ltd. (NASDAQ: OXFD)

Oxford Immunotec Ltd develops and sells clinical diagnostic products based on its patented, regulatory approved T-SPOT® technology. T-SPOT is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection. Oxford Immunotec’s first product T-SPOT®.TB, is a revolutionary new blood test for diagnosing Tuberculosis infection, offering unmatched sensitivity.

Oxford Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Status: True
Type: Private
Team: Nicholas J. Simon
Kurt C. Wheeler
Emmett Cunningham

Pearl Therapeutics acquired by AstraZeneca June 2013

Pearl Therapeutics, Inc. is a privately-held company focused on improving the treatment and prevention of widely prevalent respiratory disorders.  Pearl has licensed a suite of particle technologies from Nektar Therapeutics, Inc. to rapidly advance their product candidates through development.

Pearl Website

Fund: Clarus Lifesciences II, L.P.
Sector: Medical Device
Status: False
Type: Private
Team: Kurt C. Wheeler
Emmett Cunningham

Restoration Robotics, Inc.

Restoration Robotics, Inc., a privately held medical device company, is dedicated to revolutionizing the field of hair transplantation by developing and commercializing a state-of-the-art image-guided system (ARTAS™ System) that enables follicular unit extraction.

Restoration Robotics Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Defined Exit
Team: Robert W. Liptak
Kurt C. Wheeler
Michele Park

SFJ Pharmaceuticals, Inc.

SFJ Pharmaceuticals (SanFrancisco/Japan) serves as a clinical development specialty pharma company with a focus on obtaining product approval in Japan. Targeted candidates for development in Japan are low risk compounds that are already approved or have a high likelihood of approval in the US with projected Japan annual sales in excess of $100M. To date, SFJ has entered definitive agreements with two major global pharma companies to fund Phase 3 trials for oncology assets. Pre-determined milestone payments to SFJ shall be received on approval of the asset in pre-specified countries.

SFJ Pharmaceuticals Website

Fund: Clarus Lifesciences I, L.P.
Sector: Medical Device
Status: False
Type: Public
Team: Nicholas J. Simon
Kurt C. Wheeler
Michele Park

Sientra, Inc. (NASDAQ: SIEN)

Sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market. In April 2007, Sientra secured $85 million in a Series B financing co-led by Clarus Ventures.

Sientra Website